News
![ICON Reports Second Quarter 2022 Results : https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWRYRVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--91b049194ccf9261ff5ab4a8879b7c494da2dc48/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ICON_Positive_logo_PNG_-28nostrap-29.jpg?locale=us)
ICON Reports Second Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.
CEO Dr. Steve
![Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=us)
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![QIAGEN ergänzt digitales PCR-Portfolio QIAcuity um neue Biopharma-Produkte und führt Expert Custom Assay Design Service ein](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
QIAGEN ergänzt digitales PCR-Portfolio QIAcuity um neue Biopharma-Produkte und führt Expert Custom Assay Design Service ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute mehrere Erweiterungen seiner Instrumente für digitalen PCR (dPCR) der QIAcuity-Serie bekannt. Mit den Neuerungen soll der Einsatz des
![QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
![QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
![QIAGEN übertrifft Ausblick für zweites Quartal und erhöht Prognose für das Gesamtjahr 2022](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
QIAGEN übertrifft Ausblick für zweites Quartal und erhöht Prognose für das Gesamtjahr 2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das zweite Quartal 2022 bekannt und hob die Prognose für das Gesamtjahr 2022 an.
Der Konzernumsatz sank im
![QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
Net sales for Q2 2022 declined 9% (-4% at
![Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
![DGAP-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-Adhoc: BB Biotech AG publishes its interim report
![DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has been used to interpret more than three million
![QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass mit QIAGEN Clinical Insights (QCI), der unternehmenseigenen Plattform zur Unterstützung klinischer Entscheidungsfindungen
![Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=us)
Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with ECU Health (formerly Vidant Health), eastern North Carolina’s premier health system. The new
![ECU Health Partners With Acadia Healthcare to Build a New Behavioral Health Hospital Expanding Access to Behavioral Health Services: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=us)
ECU Health Partners With Acadia Healthcare to Build a New Behavioral Health Hospital Expanding Access to Behavioral Health Services
ECU Health and Acadia Healthcare announced today plans to build a state-of-the-art, 144-bed behavioral health hospital in the medical district of Greenville, N.C., less than a mile from ECU Health
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![AMN Healthcare Report: Orthopedic Surgeons Offered the Highest Physician Starting Salary at $565,000](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
AMN Healthcare Report: Orthopedic Surgeons Offered the Highest Physician Starting Salary at $565,000
Orthopedic surgeons are offered the highest average starting salary among physicians and advanced practice professionals, according to an annual report from AMN Healthcare and its physician search
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Acadia Healthcare Announces Date for Second Quarter 2022 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=us)
Acadia Healthcare Announces Date for Second Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2022 results on Wednesday, July 27, 2022, after the close of the market. Acadia will conduct a
![Extension of the postponement of the settlement of Vifor Pharma tender offer: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=us)
Extension of the postponement of the settlement of Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Premier, Inc. to Report Fiscal 2022 Fourth-Quarter and Full-Year Results and Host Conference Call on August 16, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVVrRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c242cfb3032e071de8936910a6c2be2320576bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/PR_LogoSpec_-282-29.jpg?locale=us)
Premier, Inc. to Report Fiscal 2022 Fourth-Quarter and Full-Year Results and Host Conference Call on August 16, 2022
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 fourth quarter and full year on Tuesday, August 16, 2022, at approximately 6:30 a.m. ET. The
![Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=us)
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2022 financial results on Wednesday, August 3rd, before the market opens. A conference call has been scheduled